GridAI Technologies (GRDX) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Metagenomi Therapeutics (MGX) over the past year, gaining 20.0% versus a loss of 68.9%. Metagenomi Therapeutics is the larger company by market cap ($37.5 million vs $34.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRDX | MGX |
|---|---|---|
| Share price | $4.80 | $0.9932 |
| Market cap | $34.23M | $37.52M |
| 1-day change | +16.50% | +0.86% |
| YTD return | +3.00% | -38.69% |
| 1-year return | +20.00% | -68.87% |
| 5-year return | -99.99% | — |
| EPS (TTM) | $-5.65 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.93 | $3.95 |
| 52-week low | $1.87 | $0.96 |
| Distance from 52-week high | -30.73% | -74.86% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +604.79% |
| Average volume | 104.68K | 158.27K |
| Shares outstanding | 7.13M | 37.78M |
| Employees | — | 113 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed MGX by 88.9 percentage points over the past year.
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Healthcare · Biotechnology
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Healthcare · Biotechnology · 113 employees
GRDX vs MGX FAQ
Which is bigger, GridAI Technologies or Metagenomi Therapeutics?
Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $37.52M compared with $34.23M for GridAI Technologies (GRDX).
Which stock has performed better over the past year, GRDX or MGX?
GRDX returned +20.00% over the past 12 months, compared with -68.87% for MGX (price return, excluding dividends). Past performance does not predict future results.
Are GridAI Technologies and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.